Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model

Sheldon Steyn, Chia-Jo Chen, Rachel Saadey, Charlene Mao, Peggy A Scherle, Neha Bhagwat, Kris Vaddi, Eric Brooks, Robert Baiocchi, Michael B. Jordan, Polina Shindiapina

Blood (2024) 144 (Supplement 1): 809.

https://doi.org/10.1182/blood-2024-208866

Published: 2024

Journal Articles

Targeting PRMT5-Mediated DNA Repair Pathway in Extra-Nodal NK/T-Cell Lymphoma (ENKTL)

Youssef Youssef, Walter Hanel, Wing Chan, Fiona C. Brown, Claire Hinterschied, Jobeth Helmig-Mason, Neha Bhagwat, Kris Vaddi, Peggy A Scherle, Amin Noorani, Sr., Aharon G. Freud, Lapo Alinari, Christopher C. Oakes, Bethany L. Mundy-Bosse, Robert Baiocchi

Blood (2024) 144 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2024-201980

Published: 2024

Journal Articles

Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

Sonali P Barwe, Neha Bhagwat, Anilkumar Gopalakrishnapillai

Blood (2024) 144 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2024-209899

Published: 2024

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Norman Fultang, Ashley M Schwab, Ian Johnson, Alexander Grego, Emma Filler, Carly Bachner, Jake Karwoski, Andrew Moore, Ashley Bartilomo, Anjana Agarwal, Olusola Peace Osinubi, Koichi Ito, Sarah Aminov, Srabani Sahu, Amit Verma, Peggy A Scherle, Neha Bhagwat, Diane Heiser

Blood (2024) 144 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2024-208196

Published: 2024

Journal Articles

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

Norman Fultang, Ashley M Schwab, Sophia McAneny-Droz, Diane Heiser, Peggy A Scherle, Neha Bhagwat

Blood (2023) 142 (Supplement 1): 5783.

https://doi.org/10.1182/blood-2023-190093

Published: 2023

Journal Articles

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Claire Hinterschied, Fiona Brown, Janani Ravikrishnan, JoBeth Helmig-Mason, Kaylee R. Harrison, Aneeq Yasin, Shelby Sloan, Mackenzie Long, Neha Bhagwat, Kris Vaddi, Peggy Scherle, Jennifer A. Woyach, Selina Chen-Kiang, Olivier Elemento, Jihye Paik, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 3118–3119.

https://doi.org/10.1182/blood-2022-167712

Published: 2022

Journal Articles

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Blood (2022) 140 (Supplement 1): 3116–3117.

https://doi.org/10.1182/blood-2022-167988

Published: 2022

Journal Articles

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

Neha Bhagwat, Bruce Ruggeri, Yang Zhang, Yaron Mosesson, Clare Killick-Cole, Veena Jagannathan, Peggy Scherle

Blood (2022) 140 (Supplement 1): 505–506.

https://doi.org/10.1182/blood-2022-158998

Published: 2022

Journal Articles

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Manish R. Patel, Varun Monga, Shekeab Jauhari, Don Stevens, Lucia Masarova, Meredith McKean, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, Andrew Moore, William Sun, Rachel Chiaverelli, Eric Mintah, Rajneesh Nath, Eytan M. Stein, Neil Palmisiano, Grerk Sutamtewagul, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2021-150938

Published: 2021

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood (2015) 126 (22): 2479–2483.

https://doi.org/10.1182/blood-2015-03-635821

Published: 2015

Includes: Supplemental data

Journal Articles

Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients

Kaitlyn R Shank, B.S., Priya Koppikar, PhD, Neha Bhagwat, PhD, Matthew D Keller, B.S., Franziska Michor, PhD, Ross L Levine, MD, Laura De Vargas Roditi, PhD

Blood (2014) 124 (21): 911.

https://doi.org/10.1182/blood.V124.21.911.911

Published: 2014

Journal Articles

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Sara C. Meyer, Matthew D. Keller, Brittany A. Woods, Lindsay M. LaFave, Lennart Bastian, Maria Kleppe, Neha Bhagwat, Sachie Marubayashi, Ross L. Levine

Blood (2014) 124 (14): 2280–2284.

https://doi.org/10.1182/blood-2014-03-560441

Published: 2014

Includes: Supplemental data

Journal Articles

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Neha Bhagwat, Priya Koppikar, Matthew Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit Rampal, Jun Qi, Maria Kleppe, Hardik J. Patel, Smit K. Shah, Tony Taldone, James E. Bradner, Gabriela Chiosis, Ross L. Levine

Blood (2014) 123 (13): 2075–2083.

https://doi.org/10.1182/blood-2014-01-547760

Published: 2014

Includes: Supplemental data

Journal Articles

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

Neha Bhagwat, B.S., Matthew D Keller, B.S., Raajit K. Rampal, M.D., Ph.D., Kaitlyn Shank, B.S., Elisa de Stanchina, PhD, Kristine Rose, PhD, Dereck Amakye, MD, Ross L. Levine, MD

Blood (2013) 122 (21): 666.

https://doi.org/10.1182/blood.V122.21.666.666

Published: 2013

Journal Articles

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Ross L. Levine, Priya Koppikar, Sachie Marubayashi, Neha Bhagwat, Tony Taldone, PhD, Christopher Y. Park, MD, PhD, Gabriela Chiosis, PhD

Blood (2012) 120 (21): 805.

https://doi.org/10.1182/blood.V120.21.805.805

Published: 2012

Journal Articles

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Neha Bhagwat, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, PhD, Mazhar Adli, Ann Mullally, MD, Omar Abdel-Wahab, MD, Laura Leung, Abby Weinstein, Sachie Marubayashi, Aviva Goel, Mithat Gonen, Zeev Estrov, Benjamin L. Ebert, MD, D.Phil, Gabriela Chiosis, PhD, Bradley Bernstein, Srdan Verstovsek, MD, PhD, Ross L Levine, MD

Blood (2011) 118 (21): 122.

https://doi.org/10.1182/blood.V118.21.122.122

Published: 2011

Journal Articles

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms.

Priya Koppikar, PhD, Sachie Marubayashi, Tony Taldone, Omar Abdel-Wahab, Nathan West, Alexander Gozman, James Ahn, Anna Rodina, Neha Bhagwat, Cyrus V. Hedvat, MD, PhD, James E. Bradner, MD, Gabriela Chiosis, Ross L. Levine, MD

Blood (2009) 114 (22): 3898.

https://doi.org/10.1182/blood.V114.22.3898.3898

Published: 2009

NARROW

Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model

Targeting PRMT5-Mediated DNA Repair Pathway in Extra-Nodal NK/T-Cell Lymphoma (ENKTL)

Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only